Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 284

Results For "MED"

6300 News Found

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr
News | August 06, 2023

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr

The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023


USFDA approves Merck’s ERVEBO for use in children 12 months of age and older
Drug Approval | August 05, 2023

USFDA approves Merck’s ERVEBO for use in children 12 months of age and older

Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease


DuPont completes acquisition of Spectrum Plastics Group
News | August 03, 2023

DuPont completes acquisition of Spectrum Plastics Group

With an annual revenue of about $500 million, Spectrum will become part of the Industrial Solutions line of business within the Electronics & Industrial segment


Syrma SGS acquires majority sake in Johari Digital Healthcare
Digitisation | August 02, 2023

Syrma SGS acquires majority sake in Johari Digital Healthcare

JDHL has a strong reputation as an end-to-end design-focused manufacturer of electro-medical devices


Fredun Pharmaceuticals achieves milestone in Pet Care Division
News | August 01, 2023

Fredun Pharmaceuticals achieves milestone in Pet Care Division

The company achieved 100% capacity utilisation in the division. These accomplishments stand as a testament to the company's dedication and vision


Concord Biotech’s IPO to open on 4th August, 2023
News | August 01, 2023

Concord Biotech’s IPO to open on 4th August, 2023

The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.


Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer
Drug Approval | August 01, 2023

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy


Fluor awarded more than $1 billion in life sciences contracts
News | August 01, 2023

Fluor awarded more than $1 billion in life sciences contracts

Contracts are related to a $487 million biotech expansion project in Denmark and first phase of a new life sciences production facility valued at $574 million in Central U.S.


New products and nutraceuticals added under Jan Aushadhi Pariyojana
Policy | July 31, 2023

New products and nutraceuticals added under Jan Aushadhi Pariyojana

The product basket increased to 1800 medicines and 285 Surgical Equipment